Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for Severe Autoimmune Encephalitis
2024-514494-21-00Phase 2Authorised
- Sponsor
- Friedrich Schiller University Jena
- Start
- Jun 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bortezomib in Autoimmune Encephalitis (AE) (2 arms), sponsored by Friedrich Schiller University Jena. Planned start Jun 2024; status: authorised.
02
Drugs
bortezomib
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on 2024-514494-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514494-21-00.